SMARCA4 and lung adenocarcinoma: In lung adenocarcinoma, where the abrogating mutation rate was found to be the highest for BRG1 at 3.0% (Atlas database; Table 1), the loss of BRG1 was still significantly frequent at 16-37% [30, 31, 34].